Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Strong Second Quarter Financial Results Second-Quarter Net Revenue of $4.4 million; Robust Growth Drives 36% Increase in Net Revenue with Third Consecutive Quarter of Profitability SOUTH ORANGE, NJ, August 7, 2025 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the ...

Financial Data and Key Metrics Changes - The trailing twelve-month revenue increased from $13.8 million to $16.7 million, reflecting a strong growth trajectory [5] - Net revenue for Q2 reached $4.4 million, up 36% compared to Q2 2024, marking the third consecutive quarter of profitability [6][9] - For the first half of 2025, revenue increased by 37% to $9.2 million from the prior year period [12] - Gross margins improved to 63% in Q2 2025 from 59% in Q2 2024, driven by reduced shipping costs and inventory reserve adjustments [10] - Net income for Q2 was $237,000, compared to a net loss of $289,000 in the same period last year [11] - Adjusted EBITDA for Q2 was positive $355,000, compared to a loss of $133,000 during the same period in 2024 [11] Business Line Data and Key Metrics Changes - The core programmatic business experienced a 40% compound growth over the past two years [7] - Protonight sales reached all-time highs, indicating the effectiveness of the recurring revenue model [7] - Active customer sites grew to over 1,600 as of June 30, 2025, slightly higher than March 31, 2025 [10] Market Data and Key Metrics Changes - Every region outperformed its first-half targets, reinforcing the resilience and scalability of the business [6] - The company is focusing on expanding into underserved verticals such as dental, government, and municipal facilities [8] Company Strategy and Development Direction - The company aims to bring new innovations to market, including the S100 micro filter and 20-inch Hydro Guard, unlocking opportunities across various sectors [8] - The strategic expansion of the sales team into non-healthcare verticals has begun to yield positive results [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of growth, attributing it to a combination of initiatives including the filter tracking app and enhanced service capabilities [20][22] - The company is focused on maintaining operational discipline while continuing to protect profitability [8] Other Important Information - Research and development expenses increased to $311,000 in Q2 2025 due to higher headcount [10] - Sales, general, and administrative expenses rose by 13% to $2.2 million, driven by higher sales commissions and employee bonuses [11] Q&A Session Summary Question: What initiatives contributed to the growth in customer retention and active sites? - Management attributed growth to a combination of the filter tracking app, service capabilities, and a focused sales team that enhances customer relationships [20][22] Question: Is the current sales force sufficient to pursue growth in new verticals? - Management acknowledged the need for an expanded sales force to effectively cover both existing customers and pursue new opportunities in different verticals [24][26]

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or other jurisdiction of ...

Exhibit 99.1 Nephros Announces Financial Results for Quarter Ended March 31, 2025 First-Quarter Net Revenue of $4.9 million; Robust Growth Drives 38% Increase in Net Revenue SOUTH ORANGE, NJ, May 8, 2025 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the first quarter ended March 31, 2025. Financial Highlights "Q1 2025 marked a strong start to the year, with a record quarterly net ...

Financial Performance - Total net revenues for the year ended December 31, 2024, decreased by 1% to $14,162,000 compared to $14,238,000 in 2023, primarily due to reduced emergency response orders [152]. - Net income for the year ended December 31, 2024, was $74,000, a significant improvement from a net loss of $1,575,000 in 2023 [152]. - The accumulated deficit as of December 31, 2024, was $144.3 million, indicating ongoing challenges in achieving profitability [163]. Expenses - Research and development expenses rose by 4% to $906,000 in 2024, mainly due to an increase in headcount [155]. - Selling, general and administrative expenses decreased by $1,235,000 or 14% to $7,676,000, primarily due to lower stock compensation and bonus expenses [157]. Cash Flow - Cash and cash equivalents decreased to $3,760,000 as of December 31, 2024, from $4,307,000 in 2023 [161]. - Net cash used in operating activities was $500,000 for the year ended December 31, 2024, compared to net cash provided of approximately $800,000 in 2023 [165]. Gross Margin and Income - Gross margin increased to 62% for the year ended December 31, 2024, up from 59% in 2023, reflecting more favorable terms with the largest supplier [154]. - Interest income increased to approximately $94,000 in 2024, up from $64,000 in 2023, due to higher interest rates on invested cash balances [158]. Future Plans - The company plans to allocate current capital resources toward the development, marketing, and sales of water filtration products [164].

Financial Performance - Full-year net revenue for 2024 was $14.2 million, remaining flat compared to 2023[6] - Fourth-quarter net revenue was $3.9 million, an increase of 19% from $3.3 million in Q4 2023[6] - Net income for the fourth quarter was $349,000, compared to a net loss of $654,000 in the same period of 2023[6] - Adjusted EBITDA for the fourth quarter was $466,000, compared to a loss of $51,000 in Q4 2023[6] - Total net revenues for Q4 2024 were $3,870,000, an increase of 18.9% compared to $3,254,000 in Q4 2023[31] - Operating income for Q4 2024 was $317,000, compared to an operating loss of $649,000 in Q4 2023[31] - Net income for Q4 2024 was $349,000, a significant turnaround from a net loss of $654,000 in Q4 2023[31] - The company reported a basic net income per share of $0.03 for Q4 2024, compared to a loss of $0.06 per share in Q4 2023[31] Revenue and Sales - The company added nearly 600 new customer sites, contributing almost $2 million in sales, representing over 13% of annual revenue[5] - Product revenues for the twelve months ended December 31, 2024, were $14,035,000, a slight decrease of 0.5% from $14,110,000 in 2023[31] Expenses and Margins - Gross margin for the year was 62%, up from 59% in 2023, and for Q4 it was 64%, compared to 62% in Q4 2023[10] - Selling, general and administrative expenses decreased by 14% year-over-year to $7.7 million for 2024[11] - Research and development expenses for the year remained steady at $0.9 million, with a 21% increase in Q4 due to higher headcount[12] - Research and development expenses for the twelve months ended December 31, 2024, were $906,000, an increase of 3.8% from $873,000 in 2023[31] - Gross margin for Q4 2024 improved to $2,475,000, representing a 22.5% increase from $2,021,000 in Q4 2023[31] Assets and Liabilities - Total current assets decreased to $8,298,000 in 2024 from $8,405,000 in 2023, reflecting a decline of 1.3%[28] - Total liabilities decreased to $2,625,000 in 2024, down 25.1% from $3,503,000 in 2023[28] - Stockholders' equity increased to $8,585,000 in 2024, up 2.7% from $8,358,000 in 2023[28] Product Development - The company launched the 20" HydraGuard Ultrafilter, targeting industries such as sterile processing and manufacturing[4] - Nephros achieved profitability for the first time in Q3 2024, attributed to effective cost control[5]

Company Participation - Nephros, Inc. will participate in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference on December 11, 2024, at the New York Athletic Club in New York City [1] - CEO Robert Banks and CFO Judy Krandel will host one-on-one and group investor meetings during the conference [2] Company Overview - Nephros is a water technology company focused on providing filtration solutions for medical and commercial markets, emphasizing water safety and quality [4] - The company aims to improve the human relationship with water through innovative filtration products and services, along with water-quality education [4]

Company Overview - The company develops and sells high-performance water filtration solutions primarily for medical and commercial markets[84]. - The company previously held a majority stake in Specialty Renal Products, which was liquidated in March 2023 due to capital exhaustion, with an outstanding loan balance of approximately $1.5 million[87]. - The company entered into a new supply agreement in January 2023 with a partner to be the exclusive distributor for food, beverage, and hospitality industries[110]. - The company entered into a License and Supply Agreement with Medica S.p.A. for the marketing and sale of filtration products based on Medica's ultrafiltration technology[151]. Medical Products - Medical water filters, classified as ultrafilters, capture contaminants as small as 0.005 microns, minimizing exposure to various pathogens[85]. - The company has FDA 510(k) clearance for multiple medical device products, including the DSU-H and SSU-H ultrafilters, with product life spans of up to 6 months in hospital settings[100]. - There are approximately 7,100 dialysis clinics in the U.S. servicing around 500,000 patients annually, with over 100,000 hemodialysis machines in operation[105]. - The company’s commercial products include the NanoGuard ultrafilter, which provides dual-stage retention of particles larger than 15,000 Daltons[113]. Financial Performance - Total net revenues decreased by $0.2 million, or 6%, for the three months ended September 30, 2024, compared to the same period in 2023, primarily due to underperformance in programmatic business[121]. - Consolidated gross margin increased to approximately 61% for the three months ended September 30, 2024, up from approximately 59% in the same period of 2023, driven by favorable pricing terms[122]. - Selling, general and administrative expenses decreased by $416,000, or 19%, primarily due to a reduction in bonus accrual and other expenses related to facilities consolidation[123]. - Research and development expenses decreased by approximately $17,000 for the three months ended September 30, 2024, due to a reduction in bonus accrual[124]. - Net income for the three months ended September 30, 2024, was $183,000, compared to a net loss of $182,000 in the same period of 2023, representing a turnaround of $365,000[120]. - Total net revenues decreased by $0.7 million, or 6%, for the nine months ended September 30, 2024, compared to the same period in 2023, primarily due to decreased revenue from emergency response orders[127]. - Consolidated gross margin for the nine months ended September 30, 2024, was approximately 61%, up from approximately 58% in the same period of 2023, attributed to favorable pricing terms and reduced shipping expenses[128]. - Net cash used in operating activities was $1.8 million for the nine months ended September 30, 2024, compared to net cash provided by operating activities of approximately $1.1 million for the same period in 2023[140]. - Cash and cash equivalents decreased to $2.457 million as of September 30, 2024, down from $4.307 million as of December 31, 2023[136]. - The company had an accumulated deficit of $144.7 million as of September 30, 2024, indicating potential ongoing operating losses until profitability is achieved[134]. Risks and Compliance - The company maintains effective disclosure controls and procedures as evaluated by the Chief Executive Officer and Chief Financial Officer[148]. - There were no changes in internal control over financial reporting that materially affected the company's reporting[149]. - The company is subject to risks related to minimum purchase obligations under the License and Supply Agreement, which could impact financial results[150]. - Failure to meet minimum purchase commitments could result in termination of the agreement, adversely affecting the company's ability to supply filtration products[152]. - The company anticipates that water safety management programs currently in medical facilities will migrate to commercial markets, potentially increasing future revenue[111]. Operational Challenges - The company’s results of operations have fluctuated significantly, influenced by market acceptance of products and expense management[118].

Financial Performance - Third-quarter net revenue was $3.5 million, an 8% increase from Q2 2024 but a 6% decrease compared to Q3 2023[2] - The company achieved a net income of $0.2 million, compared to a net loss of $0.2 million in the same period last year[2] - Adjusted EBITDA for the quarter was $295,000, a significant increase from $11,000 in Q3 2023[9] - Gross margins improved to 61% in Q3 2024, up from 59% in Q3 2023, due to better terms with the largest supplier[5] - Selling, general and administrative expenses decreased to $1.7 million from $2.1 million in the same period last year, attributed to lower stock compensation and bonus accruals[7] Cash Flow and Assets - Cash and cash equivalents as of September 30, 2024, were $2.5 million, down from $4.3 million at the end of 2023, primarily due to operating losses in the first half of 2024[10] - Total current assets decreased to $7,356,000 from $8,405,000, a decline of approximately 12.5%[22] - Cash and cash equivalents decreased to $2,457,000 from $4,307,000, a decline of approximately 42.9%[22] - Accounts receivable increased to $1,691,000 from $1,496,000, an increase of approximately 13.0%[22] - Inventory increased to $3,099,000 from $2,470,000, an increase of approximately 25.4%[22] Liabilities and Equity - Total liabilities decreased to $2,212,000 from $3,503,000, a decline of approximately 37.0%[22] - Current liabilities decreased to $1,058,000 from $2,113,000, a decline of approximately 50.0%[22] - Lease liabilities decreased to $1,154,000 from $1,390,000, a decline of approximately 17.0%[22] - Total stockholders' equity decreased to $8,174,000 from $8,358,000, a decline of approximately 2.2%[22] - Accumulated deficit increased to $(144,681,000) from $(144,406,000) indicating a deeper loss[22] - Additional paid-in capital increased slightly to $152,844,000 from $152,754,000[22] Operational Focus - The South Central region underperformed, leading to a reorganization, despite overall solid growth in most sales regions[3] - The company is preparing to launch digital support for filter installation and is enhancing service capabilities to improve customer compliance with filter change schedules[3] - Nephros is focused on maintaining positive cash flow and profitability while managing expenses and improving operational efficiency[19] Research and Development - Research and development expenses remained stable at $0.2 million for both Q3 2024 and Q3 2023[6]